|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:31916386 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] |
CTD |
PMID:27387537 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions decreases activity |
ISO |
XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased activity of ALDH1 protein] |
CTD |
PMID:31916386 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ar |
androgen receptor |
increases degradation multiple interactions |
ISO |
ginsenoside Rg3 results in increased degradation of AR protein ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein] |
CTD |
PMID:22101440 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of AREG mRNA |
CTD |
PMID:31916386 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of BAX protein] |
CTD |
PMID:26427350 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of BCL2 protein] |
CTD |
PMID:26427350 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]] |
CTD |
PMID:24394491 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein] |
CTD |
PMID:27387537 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of BIRC5 mRNA; ginsenoside Rg3 results in decreased expression of BIRC5 protein |
CTD |
PMID:19778801 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of CASP1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of CASP3 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein] |
CTD |
PMID:22101440 PMID:26427350 PMID:31916386 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP8 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP9 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of CYR61 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of CCN2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
ISO |
[Xiao-Ke-An results in increased abundance of ginsenoside Rg3] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] |
CTD |
PMID:25824408 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions affects phosphorylation |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein |
CTD |
PMID:25824408 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Epcam |
epithelial cell adhesion molecule |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of EPCAM mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein] ginsenoside Rg3 results in decreased expression of FUT4 protein |
CTD |
PMID:26427350 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein] ginsenoside Rg3 results in decreased expression of HSF1 protein |
CTD |
PMID:26427350 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
ginsenoside Rg3 results in increased expression of IL1B protein ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:14534150 PMID:34423507 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of KIT mRNA |
CTD |
PMID:31916386 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf4 |
Kruppel like factor 4 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of KLF4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Lats1 |
large tumor suppressor kinase 1 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of LATS1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 1:2,160,411...2,193,640
Ensembl chr 1:2,160,411...2,193,640
|
|
G |
Lats2 |
large tumor suppressor kinase 2 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of LATS2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein |
CTD |
PMID:31916386 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA] |
CTD |
PMID:24793912 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of MYC mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of NANOG mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases activity |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein ginsenoside Rg3 results in increased activity of NFKB1 protein |
CTD |
PMID:14534150 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein |
CTD |
PMID:14534150 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:34423507 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein] ginsenoside Rg3 results in increased expression of NOS2 mRNA |
CTD |
PMID:14534150 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] |
CTD |
PMID:24394491 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of PARP1 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein] |
CTD |
PMID:22101440 PMID:24793912 PMID:26427350 PMID:31916386 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of PCK1 mRNA |
CTD |
PMID:30144466 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of POU5F1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of PPARGC1A mRNA |
CTD |
PMID:30144466 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prom1 |
prominin 1 |
decreases expression multiple interactions |
ISO |
ginsenoside Rg3 results in decreased expression of PROM1 mRNA XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA] |
CTD |
PMID:31916386 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] |
CTD |
PMID:34423507 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:14534150 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sall4 |
spalt-like transcription factor 4 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of SALL4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822
|
|
G |
Sirt1 |
sirtuin 1 |
increases activity |
EXP |
ginsenoside Rg3 results in increased activity of SIRT1 protein |
CTD |
PMID:30144466 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein] |
CTD |
PMID:24394491 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein] |
CTD |
PMID:24394491 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of SOX2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of SP1 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] 3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk3 |
serine/threonine kinase 3 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of STK3 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:66,052,345...66,323,233
|
|
G |
Stk4 |
serine/threonine kinase 4 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of STK4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of THY1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of TNF protein |
CTD |
PMID:14534150 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]] |
CTD |
PMID:27387537 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:24793912 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of WWTR1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of YAP1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
2-Methoxyestradiol inhibits the reaction [Quercetin results in decreased phosphorylation of AKT1 protein]; [Quercetin co-treated with 2-Methoxyestradiol] results in decreased phosphorylation of AKT1 protein; Quercetin inhibits the reaction [2-Methoxyestradiol results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:26011145 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aqp1 |
aquaporin 1 |
affects expression |
EXP |
2-Methoxyestradiol affects the expression of AQP1 protein |
CTD |
PMID:21092735 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
EXP |
2-Methoxyestradiol affects the expression of AQP4 protein |
CTD |
PMID:21092735 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases phosphorylation |
ISO |
2-Methoxyestradiol results in decreased phosphorylation of BAD protein |
CTD |
PMID:23967052 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in decreased expression of BAX mRNA] |
CTD |
PMID:30154949 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of BCL2 mRNA] 2-Methoxyestradiol results in decreased expression of BCL2 protein |
CTD |
PMID:17418156 PMID:30154949 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression |
ISO |
2-Methoxyestradiol results in increased cleavage of CASP3 protein 2-Methoxyestradiol promotes the reaction [Quercetin results in increased cleavage of CASP3 protein]; Arsenic Trioxide promotes the reaction [2-Methoxyestradiol results in increased expression of CASP3 protein modified form]; Quercetin promotes the reaction [2-Methoxyestradiol results in increased cleavage of CASP3 protein] |
CTD |
PMID:23967052 PMID:26011145 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression multiple interactions |
ISO |
2-Methoxyestradiol results in increased expression of CASP7 protein modified form Arsenic Trioxide promotes the reaction [2-Methoxyestradiol results in increased expression of CASP7 protein modified form] |
CTD |
PMID:23967052 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of CASP8 protein modified form |
CTD |
PMID:23967052 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of CASP9 protein modified form |
CTD |
PMID:23967052 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CCNA2 protein |
CTD |
PMID:23967052 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
2-Methoxyestradiol results in increased expression of and results in increased activity of CCNB1 protein 2-Methoxyestradiol results in increased expression of CCNB1 protein |
CTD |
PMID:16356831 PMID:23967052 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CCND1 protein |
CTD |
PMID:23967052 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CCND3 protein |
CTD |
PMID:23967052 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CCNE2 protein |
CTD |
PMID:23967052 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
2-Methoxyestradiol results in decreased expression of and affects the phosphorylation of CDC25C protein |
CTD |
PMID:23967052 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation |
ISO |
2-Methoxyestradiol results in decreased phosphorylation of CDK1 protein |
CTD |
PMID:23967052 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CDK2 protein |
CTD |
PMID:23967052 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of CDK4 protein |
CTD |
PMID:23967052 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of CDKN1B protein |
CTD |
PMID:23967052 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Comt |
catechol-O-methyltransferase |
affects chemical synthesis |
ISO |
COMT protein affects the chemical synthesis of 2-Methoxyestradiol |
CTD |
PMID:15377160 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of CTF1 protein]; 2-Methoxyestradiol inhibits the reaction [Vitamin K 3 results in increased expression of CTF1 protein] |
CTD |
PMID:16507596 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression |
ISO |
2-Methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib] 2-Methoxyestradiol results in decreased expression of CTNNB1 mRNA; 2-Methoxyestradiol results in decreased expression of CTNNB1 protein |
CTD |
PMID:18485479 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases abundance |
ISO |
Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased abundance of 2-Methoxyestradiol]; Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [CYP1A1 protein results in increased abundance of 2-Methoxyestradiol]] |
CTD |
PMID:9706865 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of EGF mRNA; 2-Methoxyestradiol results in decreased expression of EGF protein |
CTD |
PMID:30779072 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of EGFR mRNA; 2-Methoxyestradiol results in decreased expression of EGFR protein |
CTD |
PMID:30779072 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Epo |
erythropoietin |
decreases expression multiple interactions |
EXP |
2-Methoxyestradiol results in decreased expression of EPO protein 2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of EPO protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of EPO protein] |
CTD |
PMID:31850806 PMID:32461003 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of H2AX protein modified form |
CTD |
PMID:23967052 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
EXP ISO |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of HIF1A protein]; 2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of HIF1A protein] 2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] 2-Methoxyestradiol results in decreased expression of HIF1A protein 2-Methoxyestradiol inhibits the reaction [Glucose results in increased expression of HIF1A protein] |
CTD |
PMID:21617913 PMID:28624453 PMID:30154949 PMID:31850806 PMID:32461003 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
decreases response to substance multiple interactions |
ISO |
HSD17B2 protein results in decreased susceptibility to 2-Methoxyestradiol [HSD17B2 protein results in increased metabolism of and results in decreased activity of 2-Methoxyestradiol] which results in increased chemical synthesis of 2-methoxyestrone |
CTD |
PMID:16397246 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1A protein] |
CTD |
PMID:30154949 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of IL1B protein] |
CTD |
PMID:30154949 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Nanog |
Nanog homeobox |
multiple interactions |
ISO |
2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of NANOG mRNA] |
CTD |
PMID:25822711 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of PARP1 protein modified form |
CTD |
PMID:23967052 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of POU5F1 mRNA] |
CTD |
PMID:25822711 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Prdx4 |
peroxiredoxin 4 |
increases expression |
ISO |
2-Methoxyestradiol results in increased expression of PRDX4 protein |
CTD |
PMID:18272409 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 mRNA]; 2-Methoxyestradiol inhibits the reaction [cobaltous chloride results in increased expression of PTGS2 protein] |
CTD |
PMID:28624453 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of RELA protein] |
CTD |
PMID:30154949 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression multiple interactions |
EXP |
2-Methoxyestradiol results in decreased expression of SLC2A1 protein 2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of SLC2A1 protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of SLC2A1 protein] |
CTD |
PMID:31850806 PMID:32461003 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:30154949 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases response to substance affects response to substance multiple interactions |
ISO |
SOD2 protein results in increased susceptibility to 2-Methoxyestradiol SOD2 protein affects the susceptibility to 2-Methoxyestradiol 2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of SOD2 mRNA] |
CTD |
PMID:17895890 PMID:22547077 PMID:25822711 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation affects sulfation |
ISO |
SULT1A1 protein results in increased sulfation of 2-Methoxyestradiol SULT1A1 gene polymorphism affects the sulfation of 2-Methoxyestradiol |
CTD |
PMID:16517757 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
2-Methoxyestradiol inhibits the reaction [testosterone enanthate results in increased expression of TGFB1 protein] |
CTD |
PMID:30154949 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
2-Methoxyestradiol inhibits the reaction [Glucose results in decreased expression of TJP1 protein] |
CTD |
PMID:21617913 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of TUBB4A mRNA alternative form; 2-Methoxyestradiol results in decreased expression of TUBB4A protein alternative form |
CTD |
PMID:15924336 |
|
NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 2-Methoxyestradiol |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 2-Methoxyestradiol |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 2-Methoxyestradiol |
CTD |
PMID:15117964 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects expression decreases expression multiple interactions |
EXP ISO |
2-Methoxyestradiol affects the expression of VEGFA protein 2-Methoxyestradiol results in decreased expression of VEGFA protein 2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of VEGFA protein]; 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of VEGFA protein] 2-Methoxyestradiol results in decreased expression of VEGFA mRNA; 2-Methoxyestradiol results in decreased expression of VEGFA protein 2-Methoxyestradiol inhibits the reaction [Glucose results in increased expression of VEGFA protein] 2-Methoxyestradiol promotes the reaction [Quercetin results in decreased expression of VEGFA mRNA]; 2-Methoxyestradiol promotes the reaction [Quercetin results in decreased expression of VEGFA protein]; Quercetin promotes the reaction [2-Methoxyestradiol results in decreased expression of VEGFA mRNA]; Quercetin promotes the reaction [2-Methoxyestradiol results in decreased expression of VEGFA protein] |
CTD |
PMID:21092735 PMID:21617913 PMID:26011145 PMID:31850806 PMID:32461003 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
2-Methoxyestradiol results in decreased expression of XIAP protein |
CTD |
PMID:16356831 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of BAX protein] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of BCL2 protein] asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP3 protein] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein] |
CTD |
PMID:29108773 PMID:30802477 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased expression of CASP9 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CCND1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of CYP2E1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL1B protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL1B protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL1B protein] |
CTD |
PMID:30802477 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of IL6 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of IL6 protein]] [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased secretion of IL6 protein]; asiatic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein] |
CTD |
PMID:30802477 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Carnosine co-treated with asiatic acid] inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein]; asiatic acid inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:30802477 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in decreased activity of NQO1 protein] |
CTD |
PMID:29108773 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] |
CTD |
PMID:29108773 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
asiatic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased activity of POR protein] |
CTD |
PMID:29108773 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[Glutamic Acid co-treated with asiatic acid] results in increased expression of PPARGC1A protein |
CTD |
PMID:22447225 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased activity of PTGS2 protein]] |
CTD |
PMID:30802477 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of RELA protein]] |
CTD |
PMID:30802477 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in increased secretion of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in increased secretion of TNF protein]] asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Streptozocin results in increased expression of TNF protein]]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]] |
CTD |
PMID:30802477 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
asiatic acid inhibits the reaction [Hydrogen Peroxide results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 mRNA]; asiatic acid inhibits the reaction [Rotenone results in increased expression of VDAC1 protein] |
CTD |
PMID:18802751 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32344236 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:17509559 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein] |
CTD |
PMID:22278385 PMID:33285147 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein] |
CTD |
PMID:33285147 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein] |
CTD |
PMID:22278385 |
|
NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] |
CTD |
PMID:33285147 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:22278385 PMID:30842369 PMID:33285147 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein] |
CTD |
PMID:34434659 |
|
NCBI chr13:65,969,064...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein] |
CTD |
PMID:30842369 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25604657 PMID:30842369 PMID:32344236 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein |
CTD |
PMID:32344236 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] |
CTD |
PMID:25604657 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Muc5b |
mucin 5B, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein |
CTD |
PMID:25422538 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:25604657 PMID:33285147 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] |
CTD |
PMID:25604657 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Pln |
phospholamban |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein] |
CTD |
PMID:17509559 |
|
NCBI chr20:32,629,537...32,639,559
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] |
CTD |
PMID:25604657 PMID:33285147 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rho |
rhodopsin |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 4:148,975,597...148,988,693
Ensembl chr 4:148,980,611...148,985,773
|
|
G |
Rpe65 |
retinoid isomerohydrolase RPE65 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 2:248,766,497...248,798,403
Ensembl chr 2:248,766,612...248,798,403
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] |
CTD |
PMID:25604657 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:25604657 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:30842369 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein] |
CTD |
PMID:33285147 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein |
CTD |
PMID:32344236 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
salvin results in increased phosphorylation of AKT1 protein salvin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:25178877 PMID:25271104 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
salvin inhibits the reaction [sodium arsenite results in increased expression of APAF1 protein] |
CTD |
PMID:29854073 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions increases expression decreases phosphorylation |
ISO |
salvin promotes the reaction [arsenic trioxide results in decreased phosphorylation of BAD protein] salvin results in increased expression of BAD protein salvin results in decreased phosphorylation of BAD protein |
CTD |
PMID:23239002 PMID:28918123 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
salvin inhibits the reaction [Paraquat results in increased expression of BAX protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of BAX protein] salvin inhibits the reaction [sodium arsenite results in increased expression of BAX protein] salvin results in increased expression of BAX protein |
CTD |
PMID:26577515 PMID:26686574 PMID:28918123 PMID:29854073 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein] salvin inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein] salvin results in decreased expression of BCL2 protein Acetylcysteine inhibits the reaction [salvin results in decreased expression of BCL2 protein]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Pyruvaldehyde results in decreased expression of BCL2 protein] |
CTD |
PMID:25446857 PMID:26577515 PMID:26686574 PMID:28918123 PMID:29854073 PMID:30707903 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
multiple interactions |
ISO |
salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of BCL2L2 protein] |
CTD |
PMID:24557422 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein] salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein] salvin results in increased cleavage of CASP3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP3 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of CASP3 protein]; salvin inhibits the reaction [Acrylamide results in increased expression of CASP3 mRNA]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; salvin inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP3 protein] |
CTD |
PMID:24557422 PMID:25271104 PMID:25446857 PMID:26577515 PMID:26686574 PMID:28159594 PMID:28918123 PMID:29854073 PMID:30707903 PMID:31705926 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP8 protein] salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP8 protein] |
CTD |
PMID:28918123 PMID:29854073 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases cleavage |
ISO |
salvin results in increased activity of CASP9 protein salvin inhibits the reaction [sodium arsenite results in increased cleavage of CASP9 protein] salvin results in increased cleavage of CASP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP9 protein]]; Acetylcysteine inhibits the reaction [salvin results in increased cleavage of CASP9 protein]; salvin inhibits the reaction [Acrylamide results in increased expression of CASP9 mRNA]; salvin inhibits the reaction [Paraquat results in increased activity of CASP9 protein]; salvin inhibits the reaction [Pyruvaldehyde results in increased expression of CASP9 protein]; salvin promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein] |
CTD |
PMID:23239002 PMID:26577515 PMID:26686574 PMID:28159594 PMID:28918123 PMID:29854073 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
salvin inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of CAT mRNA] salvin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:28159594 PMID:29854073 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
[salvin co-treated with Tretinoin] results in increased expression of CD14 protein; salvin promotes the reaction [Calcitriol results in increased expression of CD14 protein] |
CTD |
PMID:11504768 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
salvin results in increased expression of CDKN1B protein salvin promotes the reaction [arsenic trioxide results in increased expression of CDKN1B protein] |
CTD |
PMID:23239002 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
salvin inhibits the reaction [sodium arsenite results in increased expression of FAS protein] |
CTD |
PMID:29854073 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
salvin inhibits the reaction [Oxidopamine results in increased expression of FIS1 protein] |
CTD |
PMID:31705926 |
|
NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO EXP |
salvin results in increased expression of GCLC mRNA salvin results in increased expression of GCLC protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLC protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLC protein] |
CTD |
PMID:18329808 PMID:25446857 PMID:26577515 PMID:26686574 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein] salvin results in increased expression of GCLM protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLM protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of GCLM mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein] |
CTD |
PMID:25446857 PMID:26577515 PMID:26686574 PMID:28159594 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
salvin inhibits the reaction [sodium arsenite results in increased expression of GPT protein] |
CTD |
PMID:29854073 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
salvin inhibits the reaction [Acrylamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:28159594 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein] salvin inhibits the reaction [sodium arsenite results in decreased activity of GSR protein] salvin results in increased expression of GSR protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GSR protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein] |
CTD |
PMID:25446857 PMID:26577515 PMID:26686574 PMID:29854073 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein] salvin results in increased expression of GSTP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of GSTP1 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSTP1 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]; salvin results in increased expression of and results in increased activity of GSTP1 protein |
CTD |
PMID:25271104 PMID:26577515 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
salvin results in increased expression of HMOX1 mRNA; salvin results in increased expression of HMOX1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of HMOX1 protein] |
CTD |
PMID:18329808 PMID:23942037 PMID:26686574 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
salvin inhibits the reaction [IFNG protein results in increased abundance of Nitrites] |
CTD |
PMID:23942037 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions increases ubiquitination |
ISO |
PRKN protein affects the reaction [salvin results in increased ubiquitination of IKBKG protein] |
CTD |
PMID:31705926 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[salvin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of ITGAM protein; salvin promotes the reaction [Calcitriol results in increased expression of ITGAM protein]; salvin promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:11504768 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP ISO |
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein] salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:25446857 PMID:29854073 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:25446857 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
salvin inhibits the reaction [Oxidopamine results in decreased expression of MFN2 protein] |
CTD |
PMID:31705926 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
salvin results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25178877 PMID:28918123 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity multiple interactions |
ISO |
salvin results in increased activity of NFE2L2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased activity of NFE2L2 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSR protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of GSTP1 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of GSR protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of NQO1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of SOD2 protein]; salvin affects the localization of and results in increased activity of NFE2L2 protein; salvin inhibits the reaction [Acrylamide results in decreased expression of NFE2L2 mRNA]; salvin inhibits the reaction [Acrylamide results in decreased expression of NFE2L2 protein] |
CTD |
PMID:26577515 PMID:26686574 PMID:28159594 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
salvin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of NFKBIA protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased phosphorylation of NFKBIA protein]; salvin results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:21375325 PMID:25271104 PMID:29854073 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
salvin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:21375325 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
salvin results in increased expression of NQO1 mRNA salvin results in increased expression of NQO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of NQO1 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of NQO1 protein]; salvin inhibits the reaction [Acrylamide results in decreased expression of NQO1 mRNA] |
CTD |
PMID:18329808 PMID:26686574 PMID:28159594 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions increases expression |
ISO |
OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PRKN protein affects the reaction [salvin results in increased expression of OPA1 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 protein] |
CTD |
PMID:31705926 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression increases cleavage |
ISO EXP |
Acetylcysteine inhibits the reaction [salvin results in increased cleavage of PARP1 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein] salvin results in decreased expression of PARP1 protein |
CTD |
PMID:25446857 PMID:28918123 PMID:30707903 PMID:31705926 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PINK1 protein] |
CTD |
PMID:30707903 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity |
ISO |
salvin results in increased activity of PPARG protein |
CTD |
PMID:20696231 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions increases expression |
ISO |
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PRKN protein affects the reaction [salvin results in increased expression of OPA1 protein]; PRKN protein affects the reaction [salvin results in increased expression of RELA protein]; PRKN protein affects the reaction [salvin results in increased ubiquitination of IKBKG protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein] salvin results in increased expression of PRKN protein |
CTD |
PMID:30707903 PMID:31705926 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
salvin promotes the reaction [arsenic trioxide results in increased expression of PTEN mRNA] salvin results in increased expression of PTEN mRNA |
CTD |
PMID:23239002 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
salvin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:21375325 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with salvin] results in increased expression of RARA protein |
CTD |
PMID:11504768 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression affects localization |
ISO |
salvin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; salvin inhibits the reaction [sodium arsenite results in increased phosphorylation of and affects the localization of RELA protein] salvin results in increased expression of RELA protein salvin affects the localization of RELA protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin affects the localization of RELA protein]; PRKN protein affects the reaction [salvin results in increased expression of RELA protein]; salvin results in increased expression of and results in increased activity of RELA protein |
CTD |
PMID:21375325 PMID:25271104 PMID:29854073 PMID:31705926 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression multiple interactions |
ISO |
salvin results in increased expression of RXRA protein Calcitriol promotes the reaction [salvin results in increased expression of RXRA protein]; Tretinoin promotes the reaction [salvin results in increased expression of RXRA protein] |
CTD |
PMID:11504768 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Shc1 |
SHC adaptor protein 1 |
multiple interactions increases expression decreases expression |
ISO |
salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]; SIRT1 mutant form inhibits the reaction [salvin results in decreased expression of SHC1 protein] salvin results in increased expression of SHC1 mRNA |
CTD |
PMID:24557422 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
ISO |
Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; SIRT1 mutant form inhibits the reaction [salvin results in decreased expression of SHC1 protein] salvin results in increased expression of SIRT1 mRNA; salvin results in increased expression of SIRT1 protein |
CTD |
PMID:24557422 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
salvin inhibits the reaction [Acrylamide results in decreased expression of SOD1 mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of SOD1 protein] |
CTD |
PMID:25446857 PMID:28159594 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 mutant form inhibits the reaction [salvin results in increased expression of SOD2 protein]; NFE2L2 protein promotes the reaction [salvin results in increased expression of SOD2 protein]; salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SOD2 protein] |
CTD |
PMID:24557422 PMID:26577515 PMID:26686574 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
salvin inhibits the reaction [Oxidopamine results in decreased expression of TH protein] |
CTD |
PMID:25446857 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
salvin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21375325 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
decreases expression |
ISO |
salvin results in decreased expression of TYR mRNA |
CTD |
PMID:21071833 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein] |
CTD |
PMID:30707903 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions increases expression |
ISO |
Calcitriol promotes the reaction [salvin results in increased expression of VDR protein]; Tetradecanoylphorbol Acetate promotes the reaction [salvin results in increased expression of VDR protein]; Tretinoin promotes the reaction [salvin results in increased expression of VDR protein] |
CTD |
PMID:11504768 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19781563 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] |
CTD |
PMID:19781563 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein |
CTD |
PMID:19781563 PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rb1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19781563 PMID:22780686 PMID:25422538 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein] |
CTD |
PMID:22386813 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
EXP |
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:27470910 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases response to substance |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:22386813 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:24599032 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form] |
CTD |
PMID:26111763 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases expression |
EXP |
ginsenoside Rd results in increased expression of CAT protein |
CTD |
PMID:9933756 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA] |
CTD |
PMID:24599032 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Lpl |
lipoprotein lipase |
decreases secretion |
ISO |
ginsenoside Rd results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases response to substance |
ISO |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd |
CTD |
PMID:30545933 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr16:7,713,630...7,716,491
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport multiple interactions |
EXP ISO |
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein] |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport multiple interactions increases expression |
EXP ISO |
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]] |
CTD |
PMID:29964319 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein] |
CTD |
PMID:29964319 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
ginsenoside Rg1 results in decreased activity of ACHE protein |
CTD |
PMID:20564503 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone] |
CTD |
PMID:22484447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein] |
CTD |
PMID:30918470 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]] |
CTD |
PMID:17123556 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of BAX protein |
CTD |
PMID:28371286 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein] |
CTD |
PMID:26593335 PMID:28371286 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein |
CTD |
PMID:24386346 PMID:28371286 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
ginsenoside Rg1 results in increased activity of CASP9 protein |
CTD |
PMID:28371286 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein] |
CTD |
PMID:15606011 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CREB1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:29964319 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of FSHR protein] |
CTD |
PMID:33331133 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein] |
CTD |
PMID:29964319 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein] |
CTD |
PMID:26593335 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 PMID:29964319 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:32198087 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:29964319 PMID:30918470 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of INHA protein] |
CTD |
PMID:33331133 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rg1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein] |
CTD |
PMID:29964319 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of LHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rg1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects phosphorylation |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:22214447 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of MAPK3 protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:22214447 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24386346 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein] |
CTD |
PMID:26593335 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir23a |
microRNA 23a |
decreases expression multiple interactions |
ISO |
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
EXP |
ginsenoside Rg1 results in increased expression of MMP2 protein |
CTD |
PMID:23738715 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
ginsenoside Rg1 results in increased expression of MMP9 protein |
CTD |
PMID:23738715 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein] |
CTD |
PMID:24386346 PMID:33331133 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization increases expression |
ISO |
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:22780686 PMID:25422538 PMID:29964319 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of PIK3CA mRNA] |
CTD |
PMID:33331133 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:24386346 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of PTEN protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
ginsenoside Rg1 results in increased phosphorylation of RPS6 protein |
CTD |
PMID:24386346 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:75,451,178...75,508,142
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
morin results in decreased activity of ABCB11 protein morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity multiple interactions |
ISO |
morin results in increased activity of ABCB1 protein morin promotes the reaction [Quercetin results in increased activity of ABCB1 protein] |
CTD |
PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
morin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased activity of ACHE protein] |
CTD |
PMID:31722249 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
morin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; morin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein] |
CTD |
PMID:18629640 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein] |
CTD |
PMID:24854284 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR gene mutant form inhibits the reaction [morin results in increased expression of CYP1A1 mRNA]; AHR gene mutant form inhibits the reaction [morin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:29584932 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Excitatory Amino Acid Agonists affects the localization of AIFM1 protein] |
CTD |
PMID:19201465 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases expression |
EXP ISO |
morin inhibits the reaction [Acetaminophen results in decreased phosphorylation of AKT1 protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in decreased phosphorylation of AKT1 protein] morin results in increased expression of AKT1 mRNA |
CTD |
PMID:19201465 PMID:26767949 PMID:28689916 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
morin results in increased expression of APAF1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
morin affects the reaction [APP protein binds to APP protein] |
CTD |
PMID:18537544 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
EXP |
morin inhibits the reaction [Doxorubicin affects the expression of AQP2 protein] |
CTD |
PMID:31100273 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
morin results in decreased expression of AR mRNA |
CTD |
PMID:24726691 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
morin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein]; morin inhibits the reaction [Doxorubicin affects the expression of BAX protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; morin inhibits the reaction [titanium dioxide results in increased expression of BAX mRNA] morin results in increased expression of BAX mRNA |
CTD |
PMID:19201465 PMID:19931519 PMID:26767949 PMID:28689916 PMID:28844848 PMID:31100273 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased activity of BCHE protein] |
CTD |
PMID:31722249 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
morin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein]; morin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; morin inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; morin inhibits the reaction [titanium dioxide results in decreased expression of BCL2 mRNA] morin results in decreased expression of BCL2 mRNA |
CTD |
PMID:19931519 PMID:26767949 PMID:28689916 PMID:28844848 PMID:31100273 PMID:31722249 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
morin results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased expression of BDNF mRNA] |
CTD |
PMID:31722249 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
morin results in decreased expression of BIRC2 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
morin results in decreased expression of BIRC3 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
morin results in decreased expression of BIRC5 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP ISO |
morin inhibits the reaction [Acetaminophen results in increased activity of CASP3 protein]; morin inhibits the reaction [Acetaminophen results in increased cleavage of CASP3 protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein]; morin inhibits the reaction [Ifosfamide results in increased activity of CASP3 protein]; morin inhibits the reaction [titanium dioxide results in increased expression of CASP3 mRNA] morin results in increased activity of CASP3 protein |
CTD |
PMID:19931519 PMID:24726691 PMID:26767949 PMID:28844848 PMID:31722249 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
morin results in increased activity of CASP7 protein |
CTD |
PMID:24726691 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in increased activity of CASP9 protein]; morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 protein] |
CTD |
PMID:19931519 PMID:26767949 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]]; morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased activity of CAT protein]; morin inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; morin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists results in decreased activity of CAT protein]; morin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]; morin inhibits the reaction [Ifosfamide results in decreased activity of CAT protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in decreased activity of CAT protein]] |
CTD |
PMID:19201465 PMID:24854284 PMID:25698669 PMID:26767949 PMID:31100273 PMID:31722249 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of CCL2 protein]] |
CTD |
PMID:25698669 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
morin results in decreased expression of CCNB1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
morin results in decreased expression of CDC25C mRNA |
CTD |
PMID:28689916 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
morin results in decreased expression of CDK1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
morin results in increased expression of CDKN1A mRNA |
CTD |
PMID:28689916 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
morin results in decreased expression of CHEK2 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
[Indomethacin co-treated with morin] inhibits the reaction [Freund's Adjuvant results in increased expression of CP protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of CP protein] |
CTD |
PMID:25698669 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased activity of CTSD protein]; morin inhibits the reaction [Freund's Adjuvant results in increased activity of CTSD protein] |
CTD |
PMID:25698669 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
morin inhibits the reaction [Diethylnitrosamine results in decreased expression of CYCS protein] |
CTD |
PMID:19931519 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
morin affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] morin results in increased expression of CYP1A1 mRNA; morin results in increased expression of CYP1A1 protein AHR gene mutant form inhibits the reaction [morin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20930378 PMID:29584932 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
ISO |
morin results in increased expression of DIABLO mRNA |
CTD |
PMID:28689916 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
morin results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
morin results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
morin results in increased expression of FADD mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
morin inhibits the reaction [titanium dioxide results in increased expression of FAS mRNA] |
CTD |
PMID:28844848 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
morin results in increased expression of FASLG mRNA |
CTD |
PMID:28689916 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased expression of FOS protein] |
CTD |
PMID:31722249 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
morin inhibits the reaction [titanium dioxide results in increased expression of FSHB protein] |
CTD |
PMID:28844848 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased expression of GFAP protein] |
CTD |
PMID:31722249 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of GPT protein]; morin inhibits the reaction [Doxorubicin results in increased activity of GPT protein] |
CTD |
PMID:24854284 PMID:31100273 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in decreased phosphorylation of GSK3B protein]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of GSK3B protein modified form] |
CTD |
PMID:19931519 PMID:26767949 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein] |
CTD |
PMID:26767949 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
morin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:22698256 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA] |
CTD |
PMID:25698669 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL1B mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] [morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]]; morin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of IL1B protein]] |
CTD |
PMID:22698256 PMID:25698669 PMID:31100273 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of IL6 mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] [morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL6 mRNA] |
CTD |
PMID:22698256 PMID:25698669 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
morin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of JUN mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of JUN mRNA] |
CTD |
PMID:25698669 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
EXP |
morin inhibits the reaction [titanium dioxide results in decreased expression of KIT mRNA] |
CTD |
PMID:28844848 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
morin inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of LEP protein] |
CTD |
PMID:24854284 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
morin inhibits the reaction [titanium dioxide results in increased expression of LHB protein] |
CTD |
PMID:28844848 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19201465 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
morin inhibits the reaction [Excitatory Amino Acid Agonists results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19201465 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased activity of MAPK8 protein] |
CTD |
PMID:31722249 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
morin inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] |
CTD |
PMID:19539802 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
morin inhibits the reaction [Diethylnitrosamine results in increased expression of MMP9 protein] morin results in decreased expression of MMP9 mRNA |
CTD |
PMID:16304905 PMID:19539802 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases expression |
ISO |
morin results in increased expression of MTOR mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in decreased expression of and affects the localization of NFE2L2 protein]; morin inhibits the reaction [Acetaminophen results in increased ubiquitination of and results in decreased expression of NFE2L2 protein]; morin inhibits the reaction [Ifosfamide results in decreased expression of NFE2L2 protein] |
CTD |
PMID:26767949 PMID:31722249 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Ifosfamide results in increased activity of NOS1 protein] |
CTD |
PMID:31722249 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of NOS2 mRNA] [morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of NOS2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of NOS2 mRNA] |
CTD |
PMID:22698256 PMID:25698669 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
EXP |
morin inhibits the reaction [Doxorubicin affects the expression of NPHS1 protein] |
CTD |
PMID:31100273 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in decreased activity of NQO1 protein]; morin inhibits the reaction [Acetaminophen results in decreased expression of NQO1 protein] Morin enhances the reaction [Carbon tetrachloride increases expression of Nqo1 mRNA in liver] |
CTD RGD |
PMID:26767949 PMID:29307993 |
RGD:25823195 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
morin results in increased expression of PARP1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Diethylnitrosamine results in increased expression of PDK1 protein modified form] |
CTD |
PMID:19931519 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Phlpp2 |
PH domain and leucine rich repeat protein phosphatase 2 |
multiple interactions |
EXP |
morin inhibits the reaction [Acetaminophen results in increased expression of PHLPP2 protein] |
CTD |
PMID:26767949 |
|
NCBI chr19:37,835,125...37,901,804
Ensembl chr19:37,835,125...37,905,513
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
increases expression |
ISO |
morin results in increased expression of PIK3CB mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
decreases expression |
ISO |
morin results in decreased expression of PRKAB1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Prkce |
protein kinase C, epsilon |
decreases expression |
ISO |
morin results in decreased expression of PRKCE mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
morin inhibits the reaction [Diethylnitrosamine results in decreased expression of PTEN protein modified form] |
CTD |
PMID:19931519 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 mRNA]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein]] |
CTD |
PMID:19539802 PMID:25698669 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
morin results in decreased activity of PTPN1 protein |
CTD |
PMID:29175190 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of RELA mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of RELA mRNA]; morin inhibits the reaction [Diethylnitrosamine results in increased expression of RELA protein]; morin inhibits the reaction [Diethylnitrosamine results in increased localization of RELA protein]; morin inhibits the reaction [Excitatory Amino Acid Agonists affects the localization of and results in increased activity of RELA protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of RELA protein]] |
CTD |
PMID:19201465 PMID:19539802 PMID:25698669 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases expression |
ISO |
morin results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO EXP |
morin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] [morin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 PMID:17976262 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
morin inhibits the reaction [titanium dioxide results in decreased expression of STAR mRNA] |
CTD |
PMID:28844848 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
morin inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; morin inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 protein] |
CTD |
PMID:18629640 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
morin inhibits the reaction [[Lipopolysaccharides co-treated with Thioglycolates] results in increased expression of TNF mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; morin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] [Indomethacin co-treated with morin] inhibits the reaction [Freund's Adjuvant results in increased expression of TNF mRNA]; Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]]; morin analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; morin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]; morin inhibits the reaction [Ifosfamide results in increased expression of TNF protein]; morin inhibits the reaction [titanium dioxide results in increased expression of TNF protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of TNF protein]] |
CTD |
PMID:22698256 PMID:24854284 PMID:25698669 PMID:28844848 PMID:31100273 PMID:31722249 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
increases expression |
ISO |
morin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of TNFSF11 mRNA]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:25698669 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
morin results in increased expression of TP53 mRNA morin inhibits the reaction [Ifosfamide results in increased expression of TP53 protein] |
CTD |
PMID:28689916 PMID:31722249 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation multiple interactions |
ISO |
UGT1A1 protein results in increased glucuronidation of morin AHR gene mutant form inhibits the reaction [morin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:14557274 PMID:29584932 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of morin |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Indomethacin promotes the reaction [morin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]]; morin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]; morin promotes the reaction [Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of VEGFA protein]] |
CTD |
PMID:25698669 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
increases expression |
ISO |
morin results in increased expression of WEE1 mRNA |
CTD |
PMID:28689916 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
oltipraz results in decreased expression of ABCB11 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
oltipraz results in increased expression of ABCB1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC1 protein |
CTD |
PMID:18032408 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression |
ISO EXP |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC2 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA oltipraz results in increased expression of ABCC2 mRNA; oltipraz results in increased expression of ABCC2 protein |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:18032408 PMID:25752797 PMID:34678219 More...
|
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of ABCC3 mRNA [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA] [oltipraz results in increased expression of ABCC3 protein] which affects the export of Acetaminophen metabolite oltipraz results in increased expression of ABCC3 mRNA; oltipraz results in increased expression of ABCC3 protein |
CTD |
PMID:12920174 PMID:15833929 PMID:16837569 PMID:22496397 PMID:30114225 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions increases expression |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC4 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA] oltipraz results in increased expression of ABCC4 mRNA; oltipraz results in increased expression of ABCC4 protein oltipraz promotes the reaction [ABCC4 protein results in increased transport of Arsenic] |
CTD |
PMID:15833929 PMID:18032408 PMID:20395535 PMID:22496397 PMID:25752797 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions increases expression |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of ABCC5 protein; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA oltipraz results in increased expression of ABCC5 mRNA |
CTD |
PMID:15833929 PMID:18032408 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA oltipraz results in increased expression of ABCC6 mRNA |
CTD |
PMID:15833929 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases activity increases expression |
ISO |
oltipraz promotes the reaction [ABCG2 protein results in increased transport of Benzo(a)pyrene metabolite] oltipraz results in increased activity of ABCG2 protein oltipraz results in increased expression of ABCG2 mRNA |
CTD |
PMID:15917307 PMID:16837569 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO EXP |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
EXP ISO |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]] |
CTD |
PMID:29211853 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]] |
CTD |
PMID:29211853 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA] oltipraz results in increased activity of AHR protein |
CTD |
PMID:11959854 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases activity |
EXP |
oltipraz results in increased activity of AKR7A3 protein |
CTD |
PMID:9328168 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alb |
albumin |
decreases expression |
EXP |
oltipraz results in decreased expression of ALB mRNA |
CTD |
PMID:9395210 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA] |
CTD |
PMID:17998271 PMID:22496397 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BAX mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
[Dexamethasone co-treated with oltipraz] results in increased activity of CEBPB protein; N-acetylsphingosine inhibits the reaction [oltipraz results in increased localization of CEBPB protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter]; oltipraz results in increased localization of and results in increased activity of CEBPB protein |
CTD |
PMID:12509401 PMID:15319326 PMID:15870285 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES1 mRNA NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA] |
CTD |
PMID:30114225 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of CES2C mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA] |
CTD |
PMID:22429928 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression affects metabolic processing decreases activity affects activity |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA]; 2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]; oltipraz results in increased expression of and results in increased activity of CYP1A1 protein; resveratrol inhibits the reaction [[oltipraz promotes the reaction [AHR protein binds to CYP1A1 promoter]] which results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [oltipraz results in increased expression of CYP1A1 mRNA] CYP1A1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP1A1 mRNA; oltipraz results in increased expression of CYP1A1 protein oltipraz metabolite results in decreased activity of CYP1A1 protein oltipraz affects the activity of CYP1A1 protein |
CTD |
PMID:10775323 PMID:11959854 PMID:15831204 PMID:15890477 PMID:15920769 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression multiple interactions increases activity affects metabolic processing |
ISO EXP |
oltipraz metabolite results in decreased activity of CYP1A2 protein; oltipraz results in decreased activity of CYP1A2 protein oltipraz results in increased expression of CYP1A2 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA] oltipraz results in increased activity of CYP1A2 protein oltipraz inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3,4-dimethylimidazo(4,5-f)quinoline] CYP1A2 protein affects the metabolism of oltipraz |
CTD |
PMID:8625305 PMID:10775323 PMID:15831204 PMID:15920769 PMID:22496397 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity affects activity increases expression |
ISO |
oltipraz metabolite results in decreased activity of CYP1B1 protein oltipraz affects the activity of CYP1B1 protein oltipraz results in increased expression of CYP1B1 mRNA |
CTD |
PMID:10775323 PMID:15890477 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects metabolic processing increases expression |
EXP ISO |
CYP2B1 protein affects the metabolism of oltipraz oltipraz results in increased expression of CYP2B10 mRNA |
CTD |
PMID:15831204 PMID:15920769 PMID:17627975 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
affects metabolic processing |
EXP |
CYP2B2 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity increases expression |
ISO |
oltipraz results in decreased activity of CYP2B6 protein oltipraz results in increased expression of CYP2B6 mRNA; oltipraz results in increased expression of CYP2B6 protein |
CTD |
PMID:19833192 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
EXP |
CYP2C11 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2D1 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects activity |
ISO |
oltipraz affects the activity of CYP2E1 protein |
CTD |
PMID:10775323 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing decreases activity affects activity |
EXP ISO |
CYP3A2 protein affects the metabolism of oltipraz oltipraz metabolite results in decreased activity of CYP3A4 protein; oltipraz results in decreased activity of CYP3A4 protein oltipraz affects the activity of CYP3A4 protein |
CTD |
PMID:10775323 PMID:15831204 PMID:15920769 PMID:19833192 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects metabolic processing |
EXP |
CYP3A23-3A1 protein affects the metabolism of oltipraz |
CTD |
PMID:15831204 PMID:15920769 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
EXP ISO |
oltipraz results in increased expression of GSTA2 mRNA; oltipraz results in increased expression of GSTA2 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA] oltipraz results in increased expression of GSTA1 mRNA; oltipraz results in increased expression of GSTA1 protein 2-tert-butylhydroquinone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 mRNA]; Dexamethasone inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; N-acetylsphingosine inhibits the reaction [oltipraz results in increased expression of GSTA2 protein]; oltipraz promotes the reaction [CEBPB protein binds to GSTA2 promoter] |
CTD |
PMID:9203627 PMID:11309284 PMID:12242683 PMID:12509401 PMID:15155840 PMID:15319326 PMID:15870285 PMID:22496397 More...
|
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
EXP ISO |
oltipraz results in increased expression of GSTA3 mRNA; oltipraz results in increased expression of GSTA3 protein oltipraz results in increased expression of GSTA2 protein |
CTD |
PMID:9203627 PMID:9794803 PMID:11309284 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases activity increases expression |
EXP |
oltipraz results in increased activity of GSTA5 protein oltipraz results in increased expression of GSTA5 mRNA; oltipraz results in increased expression of GSTA5 protein |
CTD |
PMID:8051171 PMID:8625305 PMID:9203627 PMID:9328168 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of GSTA1 mRNA; oltipraz results in increased expression of GSTA1 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA] |
CTD |
PMID:11309284 PMID:22496397 |
|
NCBI chr 9:23,743,262...23,806,260
Ensembl chr 9:23,744,288...23,801,131
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions increases expression |
ISO EXP |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA] |
CTD |
PMID:9203627 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA] |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions increases expression |
ISO EXP |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA] oltipraz results in increased expression of GSTM3 protein |
CTD |
PMID:9794803 PMID:18723825 PMID:22496397 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
ISO EXP |
oltipraz results in increased expression of GSTP1 mRNA oltipraz results in increased expression of GSTP1 protein oltipraz results in increased expression of and results in increased activity of GSTP1 protein |
CTD |
PMID:9794803 PMID:15374950 PMID:16950796 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects localization increases expression |
EXP |
oltipraz affects the localization of GSTT1 protein oltipraz results in increased expression of GSTT1 protein |
CTD |
PMID:9794803 PMID:9855024 PMID:10413528 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
oltipraz results in decreased expression of IVL protein |
CTD |
PMID:10769631 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO EXP |
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]] |
CTD |
PMID:29211853 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with oltipraz] results in increased expression of MCL1 mRNA |
CTD |
PMID:19433268 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of MGMT mRNA oltipraz results in increased expression of and results in increased activity of MGMT protein |
CTD |
PMID:16950796 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
multiple interactions increases expression |
ISO |
[oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA oltipraz results in increased expression of MGST3 mRNA |
CTD |
PMID:18723825 PMID:22496397 |
|
NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects activity multiple interactions increases activity affects response to substance |
ISO EXP |
oltipraz affects the activity of NFE2L2 protein oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]] oltipraz results in increased activity of NFE2L2 protein [oltipraz co-treated with NFE2L2 protein mutant form] affects the expression of ABCG5 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA; [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B35 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC5 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ABCC6 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of ALDH1A1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTA4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM1 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM2 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of GSTM4 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of MGST3 mRNA; [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ABCC4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of ALDH1A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES1G mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CES2C mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of CYP1A2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTA4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM2 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM3 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of GSTM4 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of SULT3A1 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT1A6A mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA]; NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B36 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of ABCC3 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of CES1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz binds to and results in increased activity of NFE2L2 protein; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]] NFE2L2 protein affects the susceptibility to oltipraz |
CTD |
PMID:11309284 PMID:15833929 PMID:15919853 PMID:19150646 PMID:20086057 PMID:22429928 PMID:22496397 PMID:25752797 PMID:29211853 PMID:30114225 More...
|
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity multiple interactions increases expression |
ISO |
oltipraz results in increased activity of NQO1 protein oltipraz promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA] oltipraz metabolite results in increased expression of NQO1 protein; oltipraz results in increased expression of NQO1 mRNA; oltipraz results in increased expression of NQO1 protein [oltipraz results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [oltipraz results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [oltipraz results in increased expression of NQO1 mRNA]; oltipraz promotes the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NQO1 mRNA] |
CTD |
PMID:11309284 PMID:12407167 PMID:15919853 PMID:17627975 PMID:18488193 PMID:19144771 PMID:19785463 PMID:22496397 PMID:28959534 PMID:30114225 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Lithocholic Acid affects the localization of and results in increased activity of NR1I3 protein] |
CTD |
PMID:19433268 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
ISO |
oltipraz results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
oltipraz results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:15919853 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
oltipraz results in increased expression of SOD2 mRNA |
CTD |
PMID:9395210 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
oltipraz results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16451816 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
oltipraz inhibits the reaction [Doxorubicin results in decreased expression of UCP2 protein] |
CTD |
PMID:29061315 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT1A1 mRNA oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A7 mRNA] |
CTD |
PMID:15374950 PMID:19144771 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases expression |
ISO |
oltipraz results in increased expression of UGT1A5 mRNA |
CTD |
PMID:19144771 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions increases expression |
ISO |
oltipraz inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of UGT1A6 mRNA] oltipraz results in increased expression of UGT1A6 mRNA |
CTD |
PMID:15374950 PMID:19144771 |
|
NCBI chr 9:88,747,229...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2a3 |
UDP glucuronosyltransferase family 2 member A3 |
decreases expression |
ISO |
oltipraz results in decreased expression of UGT2A3 mRNA |
CTD |
PMID:22496397 |
|
NCBI chr14:20,572,825...20,590,295
Ensembl chr14:20,572,808...20,590,729
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
decreases expression multiple interactions |
ISO |
oltipraz results in decreased expression of UGT2B1 mRNA [oltipraz co-treated with NFE2L2 protein mutant form] results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:19144771 PMID:22496397 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases expression multiple interactions |
ISO |
oltipraz results in increased expression of UGT2B34 mRNA NFE2L2 protein affects the reaction [oltipraz results in increased expression of UGT2B34 mRNA] |
CTD |
PMID:22496397 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
A2ml1 |
alpha-2-macroglobulin-like 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of OVOS2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:161,815,111...161,857,286
Ensembl chr 4:161,814,708...161,857,343
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ABAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA panobinostat results in decreased expression of ABCA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd14a |
abhydrolase domain containing 14A |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ABHD14A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,079,139...107,089,004
Ensembl chr 8:107,079,144...107,086,985
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acad11 |
acyl-CoA dehydrogenase family, member 11 |
increases expression |
ISO |
panobinostat results in increased expression of ACAD11 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ACKR3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression multiple interactions |
ISO |
Panobinostat results in increased expression of ACP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA panobinostat results in increased expression of ACSL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
increases expression |
ISO |
panobinostat results in increased expression of ACSM3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Panobinostat results in decreased expression of ACTA2 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ada |
adenosine deaminase |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA panobinostat results in decreased expression of ADA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ADAM12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA panobinostat results in decreased expression of ADAM22 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA panobinostat results in increased expression of ADAM28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672
|
|
G |
Adamts15 |
ADAM metallopeptidase with thrombospondin type 1 motif, 15 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA panobinostat results in increased expression of ADAMTS15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
|
|
G |
Adamts17 |
ADAM metallopeptidase with thrombospondin type 1 motif, 17 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:120,445,800...120,768,204
Ensembl chr 1:120,445,749...120,768,202
|
|
G |
Adamts19 |
ADAM metallopeptidase with thrombospondin type 1 motif, 19 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA panobinostat results in increased expression of ADAMTS19 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:52,346,448...52,531,245
Ensembl chr18:52,347,428...52,530,509
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ADCYAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA panobinostat results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA panobinostat results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
|
|
G |
Adgrl3 |
adhesion G protein-coupled receptor L3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ADGRL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860
|
|
G |
Adgrv1 |
adhesion G protein-coupled receptor V1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA panobinostat results in decreased expression of ADGRV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Afap1l1 |
actin filament associated protein 1-like 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AFAP1L1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:55,183,786...55,244,174
Ensembl chr18:55,183,786...55,244,146
|
|
G |
Ahnak |
AHNAK nucleoprotein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AHNAK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,882,223...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ajap1 |
adherens junctions associated protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA panobinostat results in increased expression of AJAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA panobinostat results in decreased expression of AKAP12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein |
CTD |
PMID:18445700 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALCAM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ALDH1A2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALDH1A3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALDH1L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:20,254,196...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Alkal2 |
ALK and LTK ligand 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA panobinostat results in increased expression of ALKAL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:47,495,645...47,505,235
Ensembl chr 6:47,495,782...47,505,234
|
|
G |
Alx1 |
ALX homeobox 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:38,157,626...38,177,220
Ensembl chr 7:38,147,117...38,177,220
|
|
G |
Amer2 |
APC membrane recruitment protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AMER2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:34,525,090...34,535,660
Ensembl chr15:34,524,542...34,528,455
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA panobinostat results in increased expression of AMIGO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Ang |
angiogenin |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:24,317,733...24,323,361
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA panobinostat results in increased expression of ANGPT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA panobinostat results in increased expression of ANGPT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA panobinostat results in increased expression of ANKH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA panobinostat results in increased expression of ANKRD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:24,313,810...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Ano3 |
anoctamin 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anos1 |
anosmin 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA panobinostat results in decreased expression of KAL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:68,561,954...68,562,801
Ensembl chr10:68,561,954...68,562,801
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
panobinostat results in increased expression of ANXA1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa2 |
annexin A2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ANXA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa3 |
annexin A3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA panobinostat results in increased expression of ANXA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa9 |
annexin A9 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of AOX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1m2 |
adaptor related protein complex 1 subunit mu 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA panobinostat results in increased expression of AP1M2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:19,838,579...19,856,560
Ensembl chr 8:19,838,580...19,856,482
|
|
G |
Ap5s1 |
adaptor related protein complex 5 subunit sigma 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of AP5S1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:118,429,618...118,436,256
Ensembl chr 3:118,429,637...118,432,926
|
|
G |
Apela |
apelin receptor early endogenous ligand |
increases expression |
ISO |
Panobinostat results in increased expression of APELA mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:24,694,231...24,703,466
Ensembl chr16:24,694,324...24,703,465
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA panobinostat results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA panobinostat results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA panobinostat results in increased expression of ARHGAP18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARHGAP5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arhgap6 |
Rho GTPase activating protein 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARHGAP6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
affects expression multiple interactions |
ISO |
panobinostat affects the expression of ARID2 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA panobinostat results in increased expression of ARID5B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA panobinostat results in decreased expression of ARMH4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Arntl2 |
aryl hydrocarbon receptor nuclear translocator-like 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of ARNTL2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARRB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arx |
aristaless related homeobox |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Asb9 |
ankyrin repeat and SOCS box-containing 9 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:29,956,576...30,001,436
Ensembl chr X:29,956,576...30,001,105
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASNS mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Astn1 |
astrotactin 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ASTN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
panobinostat results in increased expression of ATF3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp13a4 |
ATPase 13A4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp23 |
ATP23 metallopeptidase and ATP synthase assembly factor homolog |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ATP23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862
|
|
G |
Atp2c2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA panobinostat results in increased expression of ATP2C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA panobinostat results in decreased expression of ATP6V0A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:31,949,863...31,979,777
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA panobinostat results in increased expression of ATP6V0A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:66,760,159...66,842,110
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA panobinostat results in increased expression of ATP6V0D2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA panobinostat results in increased expression of ATP8B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atp8b3 |
ATPase phospholipid transporting 8B3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA panobinostat results in increased expression of ATP8B3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,175,391...9,195,442
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA panobinostat results in decreased expression of ATP9A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
|
|
G |
Axin2 |
axin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA panobinostat results in increased expression of AXIN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA panobinostat results in increased expression of B3GNT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
Bace2 |
beta-secretase 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BACE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:36,707,473...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bag2 |
BAG cochaperone 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA panobinostat results in increased expression of BAG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bag5 |
BAG cochaperone 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BAMBI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Batf3 |
basic leucine zipper ATF-like transcription factor 3 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] |
CTD |
PMID:18445700 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz1a |
bromodomain adjacent to zinc finger domain, 1A |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA panobinostat results in increased expression of BAZ1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
|
|
G |
Bcl11a |
BAF chromatin remodeling complex subunit BCL11A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BCL11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO |
panobinostat affects the expression of BCL2 mRNA (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA] panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein |
CTD |
PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] panobinostat results in increased expression of BCL2L11 protein panobinostat results in decreased expression of BCL2L11 mRNA |
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Begain |
brain-enriched guanylate kinase-associated |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA panobinostat results in decreased expression of BEGAIN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:127,943,651...127,979,876
Ensembl chr 6:127,943,651...127,979,841
|
|
G |
Best4 |
bestrophin 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA panobinostat results in decreased expression of BEST4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:130,622,194...130,629,045
Ensembl chr 5:130,623,438...130,627,099
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BHLHE40 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 4:178,833,085...178,838,685
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Panobinostat results in decreased expression of BIRC5 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
Panobinostat results in increased expression of BMF mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA panobinostat results in increased expression of BMP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] r |